A comprehensive pan-cancer transcriptomic profiling study has identified the butyrophilin subfamily protein BTN3A3 as an immune-associated cancer biomarker that demonstrates gradual downregulation during advanced disease progression. Published in Discover Oncology by researchers Krishna Sayantika Deb, Rahul Shaw, and Kuntal Pal, the analysis investigated stage-wise expression patterns across diverse tumor types to assess the biomarker’s biological and clinical relevance.
The research addresses a pressing global oncology challenge, as cancer remains a major worldwide health burden marked by rising incidence and mortality rates, especially in middle- and lower-income nations. Biologically, BTN3A3 is expressed by immune modulatory cells, where the protein participates directly in vital physiological processes including T-cell activation and tumor immune surveillance.
Through differential expression analysis across multiple cancers, the investigators detected a widespread, common pattern of downregulation. A broader cross-cancer comparative analysis evaluating BTN3A1, BTN3A2, and BTN3A3 demonstrated a comparable general trend of downregulation across the subfamily; however, BTN3A3 exhibited a noticeably more pronounced reduction in expression within breast invasive carcinoma, lung adenocarcinoma, and liver hepatocellular carcinoma than its two related counterparts.
In addition to measuring transcript levels, the research team performed stage-specific DNA methylation analysis of BTN3A3 across the three examined cancer types. This epigenetic evaluation revealed an unvarying molecular pattern characterized by hypermethylation across the promoter region alongside concurrent hypomethylation within the gene body.
Subsequent gene ontology analysis identified several key immune regulatory genes, including TLR4, CD36, CCL11, and IL34, as well as growth factors like HGF, that share related pathways and exhibit a hypomethylation pattern similar to that observed in BTN3A3.
Epigenetic and expression profiles within protein-protein interaction networks further reinforced this functional connection. Interacting immune regulatory genes, such as LTF, HLA-F, and CD1D, displayed coordinated regulation patterns supporting BTN3A3’s ongoing role in maintaining immune surveillance within the tumor microenvironment across various malignant states.
Gene cluster analysis additionally revealed that BTN3A3 is co-expressed with diverse genes involved in multiple biological pathways. These include immune regulators such as PAG1, TRAV39, HLA-DQB1, MS4A2, PARP14, and POLR3B; the tumor suppressor IL6ST; transcription factors ETS1, KLF3, and NFIA; and signaling elements including G-protein coupled receptors AGRT2 and OR6S1 alongside signaling kinases MAP3K2, MET, CAMK2D, STK33, and TGFBR1.
Collectively, the integrated transcriptomic, epigenetic, and co-expression findings indicate a progressive loss of BTN3A3 expression as cancers advance through clinical stages. The study authors concluded that this steady downregulation over disease progression underscores BTN3A3’s clinical significance as a promising candidate prognostic biomarker for metastatic stage cancers.
Subject of Research: Transcriptomic profiling of BTN3A3 downregulation across cancers
Article Title: Pan-cancer transcriptomic profiling recognises butyrophylin protein BTN3A3 as an immune-associated cancer biomarker
Article References: Deb, K. S., Shaw, R., & Pal, K. (2026). Pan-cancer transcriptomic profiling recognises butyrophylin protein BTN3A3 as an immune-associated cancer biomarker. Discover Oncology. https://doi.org/10.1007/s12672-026-06094-7
Image Credits: AI Generated
DOI: 10.1007/s12672-026-06094-7
Keywords: BTN3A3, butyrophilin, transcriptomic profiling, breast invasive carcinoma, lung adenocarcinoma, liver hepatocellular carcinoma, immune surveillance, T-cell activation, DNA methylation, promoter hypermethylation, prognostic biomarker, metastatic cancer, BTN3A1, BTN3A2, TLR4, IL6ST, protein-protein interaction
Tags: breast invasive carcinomaBTN3A1BTN3A2BTN3A3butyrophilinDNA MethylationIL6STimmune surveillanceliver hepatocellular carcinomalung adenocarcinomametastatic cancerprognostic biomarkerpromoter hypermethylationprotein-protein interactionT cell activationTLR4transcriptomic profiling






